Search results for " Multiple Sclerosis"

showing 10 items of 130 documents

Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.

2021

Objective: To identify baseline factors associated with disease activity in patients with relapsing–remitting multiple sclerosis (RRMS) under teriflunomide treatment. Methods: This was an independent, multi-centre, retrospective post-marketing study. We analysed data of 1,507 patients who started teriflunomide since October 2014 and were regularly followed in 28 Centres in Italy. We reported the proportions of patients who discontinued treatment (after excluding 32 lost to follow-up) and who experienced clinical disease activity, i.e., relapse(s) and/or confirmed disability worsening, as assessed by the Expanded Disability Status Scale (EDSS). Decision tree-based analysis was performed to i…

medicine.medical_specialtyNeurologyMultiple SclerosisToluidinesHydroxybutyratesOral drugsDiseaseRelapsing-RemittingSettore MED/26Pregnancy planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideTeriflunomideNitrilesmedicineHumans030212 general & internal medicineAdverse effectRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosismedicine.diseaseSettore MED/26 - NEUROLOGIANeurologychemistryTolerabilityItalyMultiple sclerosis; Oral drugs; Teriflunomide; Crotonates; Humans; Hydroxybutyrates; Italy; Nitriles; Retrospective Studies; Toluidines; Multiple Sclerosis; Multiple Sclerosis Relapsing-RemittingCrotonatesNeurology (clinical)business030217 neurology & neurosurgeryJournal of neurology
researchProduct

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers

2015

Introduction Natalizumab (NTZ) discontinuation can be followed by multiple sclerosis (MS) disease reactivation. Currently no disease-modifying drug (DMD) has been shown to be able to abolish disease reactivation. The aims of the current study were: (1) to determine the frequency of MS reactivation after NTZ discontinuation; (2) to evaluate predictors of reactivation risk, and (3) to compare the effect of different treatments in reducing this risk. Methods Data from 132 patients with MS followed-up for 2 years before NTZ treatment and 1 year after interruption were collected from two Italian MS centers and retrospectively evaluated. Results Overall, 72 of 132 patients (54.5%) had relapses af…

medicine.medical_specialtyNeurologyNatalizumab discontinuationDiseasePharmacologyMultiple sclerosisNatalizumabInternal medicineparasitic diseasesDisease reactivationmedicineMultiple sclerosiIn patientFirst-line therapieOriginal ResearchDisease reactivation; First-line therapies; Multiple sclerosis; Natalizumab discontinuation; Rebound; Second-line therapies; Neurology (clinical); NeurologyFirst-line therapiesReboundSecond-line therapiebusiness.industryMultiple sclerosisRetrospective cohort studymedicine.diseaseDiscontinuationNeurologyTreatment strategyNeurology (clinical)businessSecond-line therapiesmedicine.drug
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct

IMPAIRED DECISION-MAKING AND DIFFUSION ORIENTATIONAL COMPLEXITY IN PEOPLE WITH MULTIPLE SCLEROSIS

2013

Objective Difficulties with decision-making have been reported in people with multiple sclerosis (MS). It is however unclear what aspect of decision making is impaired, for example whether they are more impulsive, and how any impairments relate to grey matter pathology. In this study we assess grey matter microstructure using a novel measure of the number of diffusion orientations on diffusion MRI “diffusion orientation complexity (DOC)”. We studied DOC in cortical areas known to be associated with decision making and looked at its associations with performance on the Cambridge Gambling Task (CGT). Method One hundred and five patients with MS (61 RR, 26 SP, 18 PP; mean age: 45.9 years) and …

medicine.medical_specialtySettore M-PSI/02 - Psicobiologia E Psicologia Fisiologicabusiness.industryMultiple sclerosisHippocampusGrey matterAudiologymedicine.diseaseImpulsivityPsychiatry and Mental healthmedicine.anatomical_structuremedicineMiddle frontal gyrusSurgeryNeurology (clinical)HARDI diffusion oriantational complexity multiple sclerosis DTI cognitionmedicine.symptomPrefrontal cortexbusinessAssociation (psychology)NeuroscienceDiffusion MRIJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Individualized analysis of skin thermosensory thresholds and sensitivity in heat-sensitive people with multiple sclerosis

2020

We investigated whether and how multiple sclerosis (MS) alters thresholds for perceiving increases and decreases in local skin temperature, as well as the sensitivity to progressively greater temperature stimuli, amongst heat-sensitive people with MS. Eleven MS patients (5 M/6 F; 51.1 ± 8.6 y, EDSS 5.7 ± 1.9) and 11 healthy controls (CTR; 7 M/4 F; 50.3 ± 9.0 y) performed warm and cold threshold tests on a hairy skin site, on both sides of the body. They also underwent a thermosensitivity test where they rated (visual analogue scale) perceived magnitude of 4 local skin stimuli (i.e. 22, 26, 34, 38°C). Individual thresholds and slopes of linear regression for thermosensitivity were z-transfor…

medicine.medical_specialtyskinPhysiologybusiness.industryVisual analogue scaleHairy skinMultiple sclerosisbody Temperature Regulation Multiple Sclerosis skin thermoreceptorsSkin temperatureAudiologymedicine.diseasePriority ReportHeat stressHeat sensitivethermoreceptorPhysiology (medical)Multiple SclerosimedicineThermoreceptorPatient groupbusinessbody Temperature RegulationSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' Motorie
researchProduct

Klotho and vitamin D in multiple sclerosis: an Italian study

2019

Introduction Low vitamin D levels have been recognised as an important risk factor for autoimmune diseases, including multiple sclerosis (MS). MS is a multifactorial disease, the pathogenesis of which contributes both to genetic and environmental factors. Polymorphisms in genes codifying molecules involved in vitamin D homeostasis have been associated with hypovitaminosis D. However, the influence of polymorphisms of Klotho, which codify a protein with a pivotal role in vitamin D metabolism, have never been investigated. The aim of this study was to evaluate the association among genetic variants of Klotho, namely rs1207568 and rs9536314, serum 25(OH)D3 levels, and multiple sclerosis (both …

medicine.medical_specialtyvitamin D Klotho genetic multiple sclerosisbusiness.industryMultiple sclerosisSingle-nucleotide polymorphismvitamin DGeneral Medicinemedicine.diseasemultiple sclerosisKlotho03 medical and health sciences0302 clinical medicineEndocrinologyClinical ResearchInternal medicineGenotypeGenetic predispositionVitamin D and neurologyMedicine030212 general & internal medicineAllelegeneticbusinessKlothoGenotyping
researchProduct

Frequency of Mitoxantrone related heart involvement in patients affected by Multiple Sclerosis

2010

mitoxantrone heart involvement multiple sclerosisSettore MED/26 - Neurologia
researchProduct

Positive or negative involvement of heat-shock proteins in multiple sclerosis pathogenesis: an overview.

2014

multiple sclerosiCNSheat-shock proteinmyelin antigenheat-shock proteins; multiple sclerosis; myelin antigens; CNS
researchProduct

Looking for the best therapeutical stretegy after the 24th natalizumab adiministretion. The TY-STOP study

2012

natalizumab multiple sclerosis
researchProduct

Clinical features and disease out come in patients with pediatric and young adult onset Multiple Sclerosis

2012

pediatric Multiple sclerosis young onsetSettore MED/26 - Neurologia
researchProduct